ATS Corporation — News

ATS (ATS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-30 11:01:53

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the first quarter ended June 28, 2026, before markets open on Thursday August 06, 2026. At 8:30 a.m. Eastern on August 06, 2026, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/766230709 an.

businesswire.com - 2026-07-23 19:00:00

[url="]Interactive Brokers[/url] (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea

gurufocus.com - 2026-06-30 10:00:00

ATS, BXBLY and SKY have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2026.

zacks.com - 2026-06-29 06:11:05

Investors need to pay close attention to ATS stock based on the movements in the options market lately.

zacks.com - 2026-06-22 11:55:32

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced expanded enterprise access to its Agentic AI for Talent Acquisition platform through new connectivity with more than 30 enterprise applicant tracking systems (ATS), enabling Fusemachines Agents to work directly within the systems organizations already use to manage talent and hiring. This expanded connectivity represents the first in a broader series of planned platform enhancements designed to bring AI-powered recruiting capabilities closer to the workflows, data, and systems recruiters rely on every day.

globenewswire.com - 2026-06-18 08:30:00

Not intended for UK and US audiences  Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026 international congresses. Based on the modeling, nerandomilast consistently increased median survival in both idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).1,2 Modeling predicts meaningful extensions in survival with nerandomilast, including a multi-year increase in median survival when used as monotherapy, and additional gains when added to standard treatment.1,2 Ingelheim, Germany - Long-term survival modeling of Boehringer Ingelheim's oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis (IPF) and up to 3.3 years in adults with progressive pulmonary fibrosis (PPF), compared with no therapy.1,2 These findings are based on data from the Phase III FIBRONEER™ trials and were recently presented at the ATS and EULAR 2026 international congresses.

globenewswire.com - 2026-06-18 04:05:00

ATS, BFC and CMC have been added to the Zacks Rank #5 (Strong Sell) List on June 15, 2026.

zacks.com - 2026-06-15 04:36:09

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Anne Cybulski, Interim Chief Financial Officer, will participate in the Stifel Summer Solstice Conference in Muskoka, ON on June 16, 2026. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Stifel representative or [email protected]. About ATS Corporation ATS Corporation is an industry-leading automation s.

businesswire.com - 2026-06-08 17:00:00

Securitize and Cantor Equity Partners II Announce SEC Declaration of Effectiveness of Registration Statement on Form S-4 PR New

gurufocus.com - 2026-06-05 11:00:00

ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-28 12:44:13

ATS NYSE: ATS reported higher fiscal 2026 revenue and adjusted earnings from operations, while outlining a series of restructuring actions aimed at improving margins, cash generation and capital efficiency heading into fiscal 2027.

marketbeat.com - 2026-05-28 12:10:41

ATS (ATS) came out with quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.28 per share a year ago.

zacks.com - 2026-05-28 08:16:09

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2026. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Fourth quarter highlights: Revenues were $747.1 million (adjusted revenues1 $744.3 million) compared to $574.2 million (adjusted revenues $721.1 million) a year ago. Net loss was $16.2 million compared.

businesswire.com - 2026-05-28 06:00:00

On May 20, 2026, Nordson Corp (NDSN) released its 8-K filing reporting record second-quarter fiscal 2026 results. Sales reached $741 million, up 8% year over ye

gurufocus.com - 2026-05-20 16:53:00

Securitize Reports First Quarter 2026 Results PR Newswire MIAMI, May 20, 2026 MIAMI

gurufocus.com - 2026-05-20 11:00:00

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the double-blind period of the IMPALA-2 Phase 3 clinical trial evaluating molgramostim for the treatment of aPAP. Below is a summary of the poster presented. Poster Board 401: “Rel.

businesswire.com - 2026-05-20 08:15:00

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present

gurufocus.com - 2026-05-17 15:00:00

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the fourth quarter ended March 31, 2026, before markets open on Thursday May 28, 2026. At 8:30 a.m. Eastern on May 28, 2026, the Company will host a conference call and webcast of management's quarterly remarks and follow up question and answer period with analysts. The listen-only webcast can be accessed at https://events.q4inc.com/attendee/406309619 and th.

businesswire.com - 2026-05-14 17:00:00

G's shares fall 9.4% despite Q1 results beating estimates. Weak Q2 revenue guidance overshadows strong AI-led ATS growth.

zacks.com - 2026-05-13 13:10:33

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced two scientific posters for its lead investigational drug candidate, PIPE-791, at the upcoming American Thoracic Society (ATS) 2026 International Conference. ATS 2026 will take place in Orlando, Fla. from May 15-20, 20.

businesswire.com - 2026-05-11 16:05:00